ImmuPharma "looking forward with quiet confidence" to FDA response | News Direct

ImmuPharma "looking forward with quiet confidence" to FDA response

ImmuPharma PLC
Digital Asset Direct by ImmuPharma PLC
Download PDF Download multimedia

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | May 24, 2023 11:08 AM Eastern Daylight Time

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy visited Thomas Warner at Proactive's London studio to talk about the latest news on the specialty biopharmaceutical company's p140 platform. Immupharma recently announced that the US Food and Drug Administration (FDA) has endorsed the company's proposal for a late-stage clinical trial for the treatment of chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disorder.

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

DOWNLOAD

project media

Tags

bio-techImmuPharmapharmaceuticalFDAproactiveinveststock
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.